Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

So I think that's also helped us this growth. And certainly, our two key drivers have been KEYTRUDA and GARDASIL. And when I look at KEYTRUDA back in 2019, internationally, we only had 12 indications.

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 ...